Search

Your search keyword '"Wu, Si‐pei"' showing total 39 results
Start Over Author "Wu, Si‐pei"
39 results on '"Wu, Si‐pei"'

5. Genomic and immune characteristics ofHER2‐mutated non‐small cell lung cancer and response to immune checkpoint inhibitor‐based therapy

Author

Tu, Hai‐Yan, primary, Yin, Kai, additional, Zhao, Xiaotian, additional, Ke, E‐E, additional, Wu, Si‐Pei, additional, Li, Yang‐Si, additional, Zheng, Mei‐Mei, additional, Liu, Si‐Yang Maggie, additional, Xu, Chong‐Rui, additional, Sun, Yue‐Li, additional, Lin, Jia‐Xin, additional, Bai, Xiao‐Yan, additional, Zhang, Yi‐Chen, additional, Zhou, Qing, additional, Yang, Jin‐Ji, additional, Zhong, Wen‐Zhao, additional, Wang, Bing‐Chao, additional, Zhang, Xu‐Chao, additional, Zhu, Dongqin, additional, Yang, Lingling, additional, Ou, Qiuxiang, additional, and Wu, Yi‐Long, additional

Published
2023
Full Text
View/download PDF

6. Supplementary Table S2 from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Author

Dong, Zhong-Yi, primary, Zhong, Wen-Zhao, primary, Zhang, Xu-Chao, primary, Su, Jian, primary, Xie, Zhi, primary, Liu, Si-Yang, primary, Tu, Hai-Yan, primary, Chen, Hua-Jun, primary, Sun, Yue-Li, primary, Zhou, Qing, primary, Yang, Jin-Ji, primary, Yang, Xue-Ning, primary, Lin, Jia-Xin, primary, Yan, Hong-Hong, primary, Zhai, Hao-Ran, primary, Yan, Li-Xu, primary, Liao, Ri-Qiang, primary, Wu, Si-Pei, primary, and Wu, Yi-Long, primary

Published
2023
Full Text
View/download PDF

7. Supplemental Figure 3 Functional validations of MET Y1248H and D1246N from Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Author

Li, Anna, primary, Yang, Jin-ji, primary, Zhang, Xu-chao, primary, Zhang, Zhou, primary, Su, Jian, primary, Gou, Lan-ying, primary, Bai, Yu, primary, Zhou, Qing, primary, Yang, Zhenfan, primary, Han-Zhang, Han, primary, Zhong, Wen-Zhao, primary, Chuai, Shannon, primary, Zhang, Qi, primary, Xie, Zhi, primary, Gao, Hongfei, primary, Chen, Huajun, primary, Wang, Zhen, primary, Wang, Zheng, primary, Yang, Xue-ning, primary, Wang, Bin-chao, primary, Gan, Bin, primary, Chen, Zhi-hong, primary, Jiang, Ben-yuan, primary, Wu, Si-pei, primary, Liu, Si-yang, primary, Xu, Chong-rui, primary, and Wu, Yi-long, primary

Published
2023
Full Text
View/download PDF

8. Supplemental Figure 2 Clonal progression of P02 and P04. from Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Author

Li, Anna, primary, Yang, Jin-ji, primary, Zhang, Xu-chao, primary, Zhang, Zhou, primary, Su, Jian, primary, Gou, Lan-ying, primary, Bai, Yu, primary, Zhou, Qing, primary, Yang, Zhenfan, primary, Han-Zhang, Han, primary, Zhong, Wen-Zhao, primary, Chuai, Shannon, primary, Zhang, Qi, primary, Xie, Zhi, primary, Gao, Hongfei, primary, Chen, Huajun, primary, Wang, Zhen, primary, Wang, Zheng, primary, Yang, Xue-ning, primary, Wang, Bin-chao, primary, Gan, Bin, primary, Chen, Zhi-hong, primary, Jiang, Ben-yuan, primary, Wu, Si-pei, primary, Liu, Si-yang, primary, Xu, Chong-rui, primary, and Wu, Yi-long, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure S1 from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Author

Dong, Zhong-Yi, primary, Zhong, Wen-Zhao, primary, Zhang, Xu-Chao, primary, Su, Jian, primary, Xie, Zhi, primary, Liu, Si-Yang, primary, Tu, Hai-Yan, primary, Chen, Hua-Jun, primary, Sun, Yue-Li, primary, Zhou, Qing, primary, Yang, Jin-Ji, primary, Yang, Xue-Ning, primary, Lin, Jia-Xin, primary, Yan, Hong-Hong, primary, Zhai, Hao-Ran, primary, Yan, Li-Xu, primary, Liao, Ri-Qiang, primary, Wu, Si-Pei, primary, and Wu, Yi-Long, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure legends from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Author

Dong, Zhong-Yi, primary, Zhong, Wen-Zhao, primary, Zhang, Xu-Chao, primary, Su, Jian, primary, Xie, Zhi, primary, Liu, Si-Yang, primary, Tu, Hai-Yan, primary, Chen, Hua-Jun, primary, Sun, Yue-Li, primary, Zhou, Qing, primary, Yang, Jin-Ji, primary, Yang, Xue-Ning, primary, Lin, Jia-Xin, primary, Yan, Hong-Hong, primary, Zhai, Hao-Ran, primary, Yan, Li-Xu, primary, Liao, Ri-Qiang, primary, Wu, Si-Pei, primary, and Wu, Yi-Long, primary

Published
2023
Full Text
View/download PDF

11. Supplemental Figure 4 Dose-dependent inhibition from Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Author

Li, Anna, primary, Yang, Jin-ji, primary, Zhang, Xu-chao, primary, Zhang, Zhou, primary, Su, Jian, primary, Gou, Lan-ying, primary, Bai, Yu, primary, Zhou, Qing, primary, Yang, Zhenfan, primary, Han-Zhang, Han, primary, Zhong, Wen-Zhao, primary, Chuai, Shannon, primary, Zhang, Qi, primary, Xie, Zhi, primary, Gao, Hongfei, primary, Chen, Huajun, primary, Wang, Zhen, primary, Wang, Zheng, primary, Yang, Xue-ning, primary, Wang, Bin-chao, primary, Gan, Bin, primary, Chen, Zhi-hong, primary, Jiang, Ben-yuan, primary, Wu, Si-pei, primary, Liu, Si-yang, primary, Xu, Chong-rui, primary, and Wu, Yi-long, primary

Published
2023
Full Text
View/download PDF

12. Supoemental Figure 1 Patiens do not carry T790M mutation prior to MET-TKI are more likely to have longer PFS from Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Author

Li, Anna, primary, Yang, Jin-ji, primary, Zhang, Xu-chao, primary, Zhang, Zhou, primary, Su, Jian, primary, Gou, Lan-ying, primary, Bai, Yu, primary, Zhou, Qing, primary, Yang, Zhenfan, primary, Han-Zhang, Han, primary, Zhong, Wen-Zhao, primary, Chuai, Shannon, primary, Zhang, Qi, primary, Xie, Zhi, primary, Gao, Hongfei, primary, Chen, Huajun, primary, Wang, Zhen, primary, Wang, Zheng, primary, Yang, Xue-ning, primary, Wang, Bin-chao, primary, Gan, Bin, primary, Chen, Zhi-hong, primary, Jiang, Ben-yuan, primary, Wu, Si-pei, primary, Liu, Si-yang, primary, Xu, Chong-rui, primary, and Wu, Yi-long, primary

Published
2023
Full Text
View/download PDF

22. Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy.

Author

Tu, Hai‐Yan, Yin, Kai, Zhao, Xiaotian, Ke, E‐E, Wu, Si‐Pei, Li, Yang‐Si, Zheng, Mei‐Mei, Liu, Si‐Yang Maggie, Xu, Chong‐Rui, Sun, Yue‐Li, Lin, Jia‐Xin, Bai, Xiao‐Yan, Zhang, Yi‐Chen, Zhou, Qing, Yang, Jin‐Ji, Zhong, Wen‐Zhao, Wang, Bing‐Chao, Zhang, Xu‐Chao, Zhu, Dongqin, and Yang, Lingling

Abstract

The efficacy of immunotherapy in advanced HER2‐mutated non‐small‐cell lung cancer (NSCLC) remains incomprehensively studied. A total of 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer Institute [GLCI cohort, exon 20 insertions (ex20ins): 71.0%] to compare clinical/molecular features and immune checkpoint inhibitor (ICI)‐based therapy efficacy between patients with ex20ins and non‐ex20ins. Two external cohorts (TCGA, n = 21; META‐ICI, n = 30) were used for validation. In the GLCI cohort, 68.2% of patients displayed programmed death‐ligand 1 (PD‐L1) expression < 1%. Compared with ex20ins patients, non‐ex20ins patients had more concurrent mutations in the GLCI cohort (P < 0.01) and a higher tumour mutation burden in the TCGA cohort (P = 0.03). Under ICI‐based therapy, advanced NSCLC patients with non‐ex20ins had potentially superior progression‐free survival [median: 13.0 vs. 3.6 months, adjusted hazard ratio (HR): 0.31, 95% confidence interval (CI): 0.11–0.83] and overall survival (median: 27.5 vs. 8.1 months, adjusted HR: 0.39, 95% CI: 0.13–1.18) to ex20ins patients, consistent with findings in the META‐ICI cohort. ICI‐based therapy may serve as an option for advanced HER2‐mutated NSCLC, with potentially better efficacy in non‐ex20ins patients. Further investigations are warranted in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Efficacy of immune checkpoint inhibitors in patients with non–small cell lung cancer harboring ERBB2 exon 20 insertions and non-ERBB2 exon 20 insertions.

Author

Tu, Hai-Yan, primary, Yin, Kai, additional, Ke, E-E, additional, Wu, Si-Pei, additional, Zhao, Xiaotian, additional, Li, Yang-Si, additional, Zheng, Mei-Mei, additional, Liu, Si-Yang Maggie, additional, Sun, Yue-Li, additional, Lin, Jia-Xin, additional, Bai, Xiao-Yan, additional, Zhang, Yi-Chen, additional, Zhou, Qing, additional, Yang, Jin-Ji, additional, Zhong, Wenzhao, additional, Wang, Bin-Chao, additional, Zhu, Dongqin, additional, Yang, Lingling, additional, Ou, Qiuxiang, additional, and Wu, Yi-Long, additional

Published
2022
Full Text
View/download PDF

25. Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.

Author

Tian, Hong‐xia, Chen, Zhi‐hong, Jie, Guang‐Ling, Wang, Zhen, Yan, Hong‐hong, Wu, Si‐pei, Zhang, Shui‐lian, Lu, Dan‐xia, Zhang, Xu‐chao, and Wu, Yi‐long

Subjects
GENOMICS, LUNG cancer, CANCER patients, EPIDERMAL growth factor receptors, TUMOR suppressor genes
Abstract

Objective: NF1 is a tumor suppressor gene that encodes the neurofibromin protein and negatively regulates Ras signaling. This study was aimed to investigate the molecular, clinical characteristics, and prognostic features of NF1 gene in EGFR mutant lung cancer patients. Method: The next‐generation sequencing (NGS) was used to analyze the data from lung cancer patients in the Guangdong Lung Cancer Institute (GLCI) from June 2016 to December 2020. Results: Somatic NF1 mutations were present in 4.2% (135/3220) of Chinese lung cancer patients. NF1 mutations where clearly enriched in older (p < 0.001), male (p < 0.001), and smoking (p < 0.001) patients. Patients with NF1 mutations were more likely to have TP53 (p = 0.003), BRAF (p = 0.001) and RASA1 (p = 0.026) mutations and mutually exclusive with EGFR mutations (p = 0.006). TP53 mutation had worsen prognosis in cases of NF1 mutant (p = 0.026) or EGFR/NF1 co‐mutant (p = 0.031) lung adenocarcinomas (LUAD) patients. There was no effect on overall survival (OS) in LUAD patients with and without NF1 mutations, even in LUAD driver‐gene negative patients. NF1/EGFR co‐mutation patients had a longer OS than a single mutation of either the EGFR gene (median OS: 47.7 m vs. 30.2 m, hazard ratio [95% CI], 0.47 [0.30–0.74], p = 0.004) or NF1 gene (47.7 m vs. 19.0 m, 0.44 [0.27–0.73], p = 0.003). Furthermore, NF1 mutations significantly prolonged OS in EGFR mutant/TP53 wild‐type LUAD patients (106.5 m vs. 25.5 m, 0.28 [0.13–0.59], p = 0.003) but not in patients with EGFR/TP53 co‐mutations (36.8 m vs. 30.2 m, 0.70 [0.39–1.26], p = 0.280). Conclusion: Our results indicated NF1 mutations served as a good prognostic factor in EGFR mutant/TP53 wild‐type lung cancer patients in this single‐center study. TP53 mutation was obviously enriched in NF1 mutant patients and had shorter OS. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Author

Li, Anna, primary, Yang, Jin-ji, additional, Zhang, Xu-chao, additional, Zhang, Zhou, additional, Su, Jian, additional, Gou, Lan-ying, additional, Bai, Yu, additional, Zhou, Qing, additional, Yang, Zhenfan, additional, Han-Zhang, Han, additional, Zhong, Wen-Zhao, additional, Chuai, Shannon, additional, Zhang, Qi, additional, Xie, Zhi, additional, Gao, Hongfei, additional, Chen, Huajun, additional, Wang, Zhen, additional, Wang, Zheng, additional, Yang, Xue-ning, additional, Wang, Bin-chao, additional, Gan, Bin, additional, Chen, Zhi-hong, additional, Jiang, Ben-yuan, additional, Wu, Si-pei, additional, Liu, Si-yang, additional, Xu, Chong-rui, additional, and Wu, Yi-long, additional

Published
2017
Full Text
View/download PDF

28. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Author

Dong, Zhong-Yi, primary, Zhong, Wen-Zhao, additional, Zhang, Xu-Chao, additional, Su, Jian, additional, Xie, Zhi, additional, Liu, Si-Yang, additional, Tu, Hai-Yan, additional, Chen, Hua-Jun, additional, Sun, Yue-Li, additional, Zhou, Qing, additional, Yang, Jin-Ji, additional, Yang, Xue-Ning, additional, Lin, Jia-Xin, additional, Yan, Hong-Hong, additional, Zhai, Hao-Ran, additional, Yan, Li-Xu, additional, Liao, Ri-Qiang, additional, Wu, Si-Pei, additional, and Wu, Yi-Long, additional

Published
2017
Full Text
View/download PDF

29. The predictive value of uncommon EGFR mutation in patients with non-small-cell lung cancer.

Author

Tu, Haiyan, primary, Ke, Ee, additional, Sun, Yue-Li, additional, Zheng, Ming-Ying, additional, Yang, Jin-Ji, additional, Wang, Zhen, additional, Wu, Si-Pei, additional, Su, Jian, additional, Zhang, Xuchao, additional, Bai, Xiao-Yan, additional, Yang, Xue-Ning, additional, Zhong, Wenzhao, additional, Yan, Hong-Hong, additional, Zhou, Qing, additional, and Wu, Yi-Long, additional

Published
2017
Full Text
View/download PDF

36. Lung Cancer

Author

Velez, Maria A., primary, Wu, Yi-Long, additional, Dubinett, Steven M., additional, Dong, Zhong-Yi, additional, Wu, Si-Pei, additional, and Garon, Edward B., additional

Full Text
View/download PDF

39. [Relation of advanced oxidation protein products with VEGF and TGF-β1 in colon cancer cells exposed to intermittent hypoxia].

Author

Xian LW, Li TP, Wei YE, Wu SP, and Ma L

Subjects
Cell Hypoxia, Cell Line, Tumor, Humans, Advanced Oxidation Protein Products metabolism, Colonic Neoplasms metabolism, Oxidative Stress, Transforming Growth Factor beta1 metabolism, Vascular Endothelial Growth Factor A metabolism
Abstract

Objective: To investigate the association of advanced oxidation protein products (AOPP) with oxidative stress in colon cancer cells exposed to intermittent hypoxia (IH)., Methods: Colon cancer SW480 cells were exposed to IH, continuous hypoxia, or normoxia. Enzyme-linked immunosorbent assay (ELISA) was employed to examine the levels of AOPP and vascular endothelial growth factor (VEGF), xanthine oxidase assay was used to determine malonaldehyde (MDA) and glutathione peroxidase (GSH-PX), and Western blotting and immunofluorescence assay were performed for detection of transforming growth factor-β(1) (TGF-β(1)) expression., Results: Compared with the normoxia group, the two hypoxia groups showed significantly increased AOPP and MDA levels (P<0.05) and lowered SOD and GSH-PX levels (P<0.05). The concentration of AOPP was positively correlated to MDA, VEGF, and TGF-β(1) levels (P<0.05), but inversely to SOD. No significant correlation was found between AOPP and GSH-PX levels., Conclusion: Compared with continuous hypoxia, IH results in more obvious protein oxidation in relation to oxidative stress. The increased expression of VEGF and TGF-β(1) in the context of hypoxia is closely related to AOPP level.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results